We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

Back to rankings

2 hedge funds and large institutions have $267K invested in Aratana Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 100 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 103 → 2 (-101)

100% less capital invested

Capital invested by funds: $200M → $267K (-$200M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 100

Holders
2
Holders Change
-101
Holders Change %
-98.06%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
100
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$37.5M
2
BlackRock
BlackRock
New York
-$19.3M
3
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$16.4M
4
WIC
Water Island Capital
New York
-$14.7M
5
Man Group
Man Group
United Kingdom
-$14.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
– -$1.51M -293,333 Closed
BRCA
27
Birch Run Capital Advisors
Texas
– -$1.49M -288,200 Closed
GH
28
GAM Holding
Switzerland
– -$1.3M -253,000 Closed
PCM
29
Pentwater Capital Management
Florida
– -$1.03M -200,000 Closed
Bank of New York Mellon
30
Bank of New York Mellon
New York
– -$874K -169,284 Closed
William Blair & Company
31
William Blair & Company
Illinois
– -$742K -143,710 Closed
California Public Employees Retirement System
32
California Public Employees Retirement System
California
– -$622K -120,635 Closed
Charles Schwab
33
Charles Schwab
California
– -$608K -117,692 Closed
NSEDCP
34
NJ State Employees Deferred Compensation Plan
New Jersey
– -$568K -110,000 Closed
DAM
35
Deltec Asset Management
New York
– -$549K -106,410 Closed
PPA
36
Parametric Portfolio Associates
Washington
– -$519K -100,644 Closed
HM
37
Harvest Management
New York
– -$516K -100,000 Closed
Two Sigma Investments
38
Two Sigma Investments
New York
– -$440K -85,308 Closed
GCL
39
Glazer Capital LLC
New York
– -$439K -85,000 Closed
Morgan Stanley
40
Morgan Stanley
New York
– -$426K -82,569 Closed
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
– -$384K -74,479 Closed
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
– -$344K -66,578 Closed
AllianceBernstein
43
AllianceBernstein
Tennessee
– -$338K -65,450 Closed
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
– -$324K -62,700 Closed
SO
45
STRS Ohio
Ohio
– -$299K -58,000 Closed
BCM
46
Bridgeway Capital Management
Texas
– -$272K -52,783 Closed
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
– -$237K -46,001 Closed
CSS
48
Cubist Systematic Strategies
Connecticut
– -$235K -45,565 Closed
Deutsche Bank
49
Deutsche Bank
Germany
– -$178K -34,964 Closed
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$169K -32,806 Closed
1
2
3 4 5

PETX Hedge Fund Activity: Q3 2019 in Review

2 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2019, worth a combined $267K — down 100% from $200M a quarter earlier.

Sellers outnumbered buyers: 100 funds closed out of PETX and 0 opened new positions — a net loss of 100 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Broadfin Capital, exiting entirely with an estimated $37.5M sold.

  • 2 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2019, down from 103 in Q2 2019.
  • Funds reported $267K of Aratana Therapeutics, Inc. stock for Q3 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Aratana Therapeutics, Inc. positions in Q3 2019 and 100 closed out, a net change of -100 holders.
  • The largest Aratana Therapeutics, Inc. seller in Q3 2019 was Broadfin Capital, an estimated $37.5M sold.

Based on aggregated 13F filings for Q3 2019.